BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32198315)

  • 1. Genetic Determinants of Pheochromocytoma and Paraganglioma Imaging Phenotypes.
    Taïeb D; Pacak K
    J Nucl Med; 2020 May; 61(5):643-645. PubMed ID: 32198315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups.
    Taïeb D; Jha A; Treglia G; Pacak K
    Endocr Relat Cancer; 2019 Nov; 26(11):R627-R652. PubMed ID: 31561209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma.
    Taïeb D; Pacak K
    Cell Tissue Res; 2018 May; 372(2):393-401. PubMed ID: 29450723
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET detectives: Molecular imaging for phaeochromocytomas and paragangliomas in the genomics era.
    Ryder SJ; Love AJ; Duncan EL; Pattison DA
    Clin Endocrinol (Oxf); 2021 Jul; 95(1):13-28. PubMed ID: 33296100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetics and imaging of pheochromocytomas and paragangliomas: current update.
    Katabathina VS; Rajebi H; Chen M; Restrepo CS; Salman U; Vikram R; Menias CO; Prasad SR
    Abdom Radiol (NY); 2020 Apr; 45(4):928-944. PubMed ID: 31069476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced uptake pattern on
    de Jong MC; Pinto D; Parameswaran R
    J Surg Oncol; 2023 Oct; 128(5):764-768. PubMed ID: 37403579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Subtyping of Pheochromocytoma and Paraganglioma by
    van Berkel A; Vriens D; Visser EP; Janssen MJR; Gotthardt M; Hermus ARMM; Geus-Oei LF; Timmers HJLM
    J Nucl Med; 2019 Jun; 60(6):745-751. PubMed ID: 30413658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current experts' views on precision nuclear medicine imaging of phaeochromocytoma and paraganglioma.
    Taïeb D; Pacak K
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2223-2224. PubMed ID: 31332495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
    Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of
    Han S; Suh CH; Woo S; Kim YJ; Lee JJ
    J Nucl Med; 2019 Mar; 60(3):369-376. PubMed ID: 30030341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.
    Björklund P; Pacak K; Crona J
    J Intern Med; 2016 Dec; 280(6):559-573. PubMed ID: 27165774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
    Baysal BE; Maher ER
    Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine.
    Burnichon N; Buffet A; Gimenez-Roqueplo AP
    Curr Opin Oncol; 2016 Jan; 28(1):5-10. PubMed ID: 26599293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the management of pheochromocytoma and paraganglioma.
    Tanabe A; Naruse M
    Hypertens Res; 2020 Nov; 43(11):1141-1151. PubMed ID: 32778780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Significance of Quantitative 123I-MIBG SPECT/CT Analysis of Pheochromocytoma and Paraganglioma.
    Nakamoto R; Nakamoto Y; Ishimori T; Togashi K
    Clin Nucl Med; 2016 Nov; 41(11):e465-e472. PubMed ID: 27607159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodality Radionuclide Imaging in a Patient With Hereditary Paraganglioma-Pheochromocytoma Syndrome.
    Yim SY; Moncayo VM; Pasquel FJ; Halkar RK
    Clin Nucl Med; 2017 Dec; 42(12):964-965. PubMed ID: 28902732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study.
    Blanchet EM; Taieb D; Millo C; Martucci V; Chen CC; Merino M; Herscovitch P; Pacak K
    J Nucl Med; 2015 Dec; 56(12):1849-54. PubMed ID: 26359261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.